Literature DB >> 23730842

Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients.

S Petta1, S Grimaudo, V D Marco, C Scazzone, F S Macaluso, C Cammà, D Cabibi, R Pipitone, A Craxì.   

Abstract

Lower 25-hydroxyvitamin D [25(OH)D] serum levels have been associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients (G1CHC). In addition, a recent genome-wide study identified genetic variants (rs12785878, near dehydrocholesterol reductase, DHCR7; rs10741657, near CYP2R1; and rs7041, near vitamin D-binding protein, GC) affecting 25(OH)D serum levels in healthy populations. We aimed to assess the association between vitamin D serum levels and its genetic determinants, with the severity of liver fibrosis. Two hundred and sixty patients with biopsy-proven G1CHC were consecutively evaluated. The 25(OH)D serum levels were measured by high-pressure liquid chromatography. All patients were genotyped for DHCR7 rs12785878, CYP2R1 rs10741657 and GC rs7041 single nucleotide polymorphisms. DHCR7 GG genotype (P = 0.003) and the severity of fibrosis (P = 0.03) were independent factors associated with lower 25(OH)D serum levels in multiple linear regression analysis. Interestingly, 53.8% (7/13) of patients with DHCR7 GG genotype had severe liver fibrosis, compared to 27.1% (67/247) of those with DHCR7 TT/TG genotype (P = 0.03). By multivariate logistic regression analysis, severe fibrosis was independently associated with older age (OR, 1.056; 95% CI, 1.023-1.089, P = 0.001), low cholesterol (OR, 0.984; 95% CI, 0.974-0.994, P = 0.002), high triglycerides (OR, 1.008; 95% CI, 1.002-1.015, P = 0.01), low 25(OH)D (OR, 0.958; 95% CI, 0.919-0.999, P = 0.04), DHCR7 GG genotype (OR, 4.222; 95% CI, 1.106-16.120; P = 0.03), moderate-severe steatosis (OR, 2.588; 95% CI, 1.355-4.943; P = 0.004) and moderate-severe necroinflammatory activity (grading) (OR, 2.437; 95% CI, 1.307-4.763; P = 0.001). No associations were found between liver fibrosis and both CYP2R1 and GC genotypes. In patients with G1CHC, GG homozygosis for DHCR7 gene and lower 25(OH)D levels are independently associated with the severity of liver fibrosis.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730842     DOI: 10.1111/jvh.12072

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  23 in total

Review 1.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

2.  25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Authors:  Arthur Belle; Emmanuel Gizard; Guillaume Conroy; Anthony Lopez; Magali Bouvier-Alias; Stéphanie Rouanet; Laurent Peyrin-Biroulet; Jean-Michel Pawlotsky; Jean-Pierre Bronowicki
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

Review 3.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 4.  Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis.

Authors:  Yue-qiu Luo; Xiao-xing Wu; Zong-xin Ling; Yi-wen Cheng; Li Yuan; Charlie Xiang
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

Review 5.  Vitamin D deficiency in chronic liver disease.

Authors:  Paula Iruzubieta; Álvaro Terán; Javier Crespo; Emilio Fábrega
Journal:  World J Hepatol       Date:  2014-12-27

6.  Genetic variations in vitamin D receptor were associated with the outcomes of hepatitis C virus infection among Chinese population.

Authors:  Meng-ping Wu; Jin-wei Zhang; Peng Huang; Ya-ping Han; Yun Zhang; Zhi-hang Peng; Jie Wang; Ping Zhu; Jing Su; Rong-bin Yu; Jun Li; Ming Yue
Journal:  J Hum Genet       Date:  2015-10-08       Impact factor: 3.172

Review 7.  Vitamin D and Osteoporosis in HIV/HCV Coinfected Patients: A Literature Review.

Authors:  Paola Di Carlo; Lucia Siracusa; Giovanni Mazzola; Piero Colletti; Maurizio Soresi; Lydia Giannitrapani; Valentina Li Vecchi; Giuseppe Montalto
Journal:  Int J Endocrinol       Date:  2015-07-27       Impact factor: 3.257

Review 8.  Metabolic factors and chronic hepatitis C: a complex interplay.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Maria Giovanna Minissale; Teresa Li Vigni; Simona Attardo; Emanuele Orlando; Salvatore Petta
Journal:  Biomed Res Int       Date:  2013-07-17       Impact factor: 3.411

Review 9.  Genetic architecture of human fibrotic diseases: disease risk and disease progression.

Authors:  Agnès Gardet; Timothy S Zheng; Joanne L Viney
Journal:  Front Pharmacol       Date:  2013-12-18       Impact factor: 5.810

10.  Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients.

Authors:  Georgios Grammatikos; Christian Lange; Simone Susser; Susanne Schwendy; Nektarios Dikopoulos; Peter Buggisch; Jens Encke; Gerlinde Teuber; Tobias Goeser; Robert Thimme; Hartwig Klinker; Wulf O Boecher; Ewert Schulte-Frohlinde; Marissa Penna-Martinez; Klaus Badenhoop; Stefan Zeuzem; Thomas Berg; Christoph Sarrazin
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.